Angiogenesis inhibition in a murine mouse model of tamoxifen-induced adenomyosis through the administration of axitinib, a VEGF-R2 tyrosine kinase inhibitor, leads to a reduction in the severity of adenomyosis. The gene discussed is KDR; the disease is adenomyosis.